- Drugs used on Primary Care for the treatment of erectile dysfunction (ED)
- Safety pen needles and safety lancet devices – Commissioning Statement
- 20211209 Individual Funding Request Policy
- 20191202-IFR-application-form
- Funding for Experimental and Unproven Treatments
- On-going access to treatment following a trial of treatment which has not been sanctioned by STWCCG.
- On-going access to treatment following the completion of a trial explicitly funded by STWCCG
- On-going access to treatment following the completion of industry sponsored clinical trials or funding.
- On-going access to treatment following the completion of non-commercially funded clinical trials
- Ethical framework for priority setting and resource allocation allocation
- Policy for Joint Working with the Pharmaceutical Industry
- STW Rebates List April 22
- Continuous Glucose Monitoring (CGM) for Type 1 Diabetes in Adults and Pregnant women with Type 1 or Type 2 Diabetes on insulin therapy
- Continuous Glucose Monitoring (CGM) for Type 1 Diabetes in Children and Young People
- The use of Flash Glucose Monitoring systems in eligible diabetic patients
- Flash Glucose Monitoring prior approval initiation form
- Flash Glucose Monitoring continuation form
- Flash Glucose Monitoring previously self funding form
- Continuous Subcutaneous Insulin Infusion (CSII) without CGM in adults and children with Type 1 Diabetes
- Gluten Free Food Policy V2
- Botulinum Toxin Policy
- Non-Medical Prescribing Policy v4 Feb 2022
- Insulin degludec for Type 1 and restricted use in Type 2 diabetes
- Bath and Shower preparations in Primary Care Policy V2
